[go: up one dir, main page]

Becker, 1993 - Google Patents

Reocclusion following successful thrombolysis: emerging concepts

Becker, 1993

Document ID
17744397435855415852
Author
Becker R
Publication year
Publication venue
Cardiology

External Links

Snippet

Thrombolytic therapy, through the restoration of coronary arterial blood flow and myocardial perfusion significantly improves outcome among patients with acute myocardial infarction. Despite its widely appreciated benefits, however, thrombolysis removes only a small portion …
Continue reading at karger.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof

Similar Documents

Publication Publication Date Title
Esmon The roles of protein C and thrombomodulin in the regulation of blood coagulation
DK175704B1 (en) Inhibition of arterial thrombotic occlusion or thromboembolism
Klement et al. A novel approach to arterial thrombolysis
Klement et al. The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model
US20090226413A1 (en) Methods, Devices, And Compositions For Lysis Of Occlusive Blood Clots While Sparing Wound Sealing Clots
JP2000513720A (en) Modified factor VII
Mellott et al. Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis.
Giannini et al. Thrombolytic therapy in peripheral arterial disease
Persson et al. Streptokinase as an adjunct to arterial surgery
Weitz et al. New anticoagulant strategies
Chesebro et al. Dynamic thrombosis and thrombolysis. Role of antithrombins.
Becker Reocclusion following successful thrombolysis: emerging concepts
Ahmed et al. Biological and thrombolytic properties of fibrolase-a new fibrinolytic protease from snake venom
Klatte et al. Fibrinolytic therapy.
Wagstaff et al. Alteplase: a reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction
Cowley Methodologic aspects of intracoronary thrombolysis: drugs, dosage and duration
Topol et al. Applicability of percutaneous transluminal coronary angioplasty to patients with recombinant tissue plasminogen activator mediated thrombolysis
Gurbel et al. Lesion‐directed administration of alteplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty
Teirstein et al. Low-versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion
Sudo et al. Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous rethrombosis: a comparison with heparin
Gulba et al. Potentiative effect of heparin in thrombolytic therapy of evolving myocardial infarction with natural pro-urokinase
Ahmad et al. Platelet membrane-mediated coagulation protease complex assembly
Pasche et al. Platelets and fibrinolysis
Apprill et al. Ancrod decreases the frequency of cyclic flow variations and causes thrombolysis following acute coronary thrombosis
Tiefenbrunn et al. Factors contributing to the emergence of coronary thrombolysis